Last reviewed · How we verify
QRX-3
At a glance
| Generic name | QRX-3 |
|---|---|
| Also known as | Eseronate |
| Sponsor | Ebima Clifford Okundaye |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) (PHASE2, PHASE3)
- Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression (PHASE2, PHASE3)
- Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease
- Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QRX-3 CI brief — competitive landscape report
- QRX-3 updates RSS · CI watch RSS
- Ebima Clifford Okundaye portfolio CI